|

Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.

RECRUITINGPhase 4Sponsored by Erasmus Medical Center
Actively Recruiting
PhasePhase 4
SponsorErasmus Medical Center
Started2024-02-23
Est. completion2025-11-01
Eligibility
Age18 Years – 120 Years
Healthy vol.Accepted

Summary

The primary objective is to evaluate the effect of loading boluses when dose incresaing treatment with SC fentanyl in patients with cancer. The primary endpoint of this study is to prove the non-inferiority of fentanyl plasma concentrations 12 hours after dose augmentation compared to 48 hours after dose augmentation within each patient. Patients will be treated with additional loading boluses and plasma-PK samples will be obtained.

Eligibility

Age: 18 Years – 120 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years;
* Able to understand the written information and able to give informed consent.
* Current or planned treatment with SC fentanyl for cancer-related pain

Exclusion Criteria:

* Pregnancy or/ and breastfeeding
* Other ways of using fentanyl (sublingual, nasal spray and oromucosal)
* Liver function CPS B or C
* The use of strong CYP3A4 inhibitors of inducers \[9\]
* Presence of somnolence, respiratory depression or CTCAE grade 2 adverse events.

Conditions2

CancerCancer Pain

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.